Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients

Özkan, Elgin; Tokmak, Emel; Küçük, Ömer

doi:10.1007/s12149-011-0482-2

Cited by 8 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…111 In, emitting 1.84 gamma ray photons per decay, with a convenient for SPECT energy 171 and 245 keV is the radioisotope which can be considered as a theranostic agent upon attachment to the appropriate targeting biomolecule ( Levine and Krenning, 2017 ; Pencharz et al, 2018 ). In this way beginning with Krenning’s work ( Krenning et al, 1994 ) it had been being demonstrated that using therapeutic doses of the radiopharmaceutical [ 111 In-DTPA]- D -Phe 1 -octreotide ( 111 In-octreotide) for treatment of neuroendocrine tumors does not lead to severe side effects ( Janson et al, 1999 ; Caplin et al, 2000 ; Anthony et al, 2002 ; Valkema et al, 2002 ; Buscombe et al, 2003 ; Nguyen et al, 2004 ; Kong et al, 2009 ; Ozkan et al, 2011 ). More than 140 cases of therapy using this radiopharmaceutical are analyzed in these papers.…”

Section: Introductionmentioning

confidence: 99%

Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression

et al. 2018

View full text Add to dashboard Cite

Gamma-ray emitting 111In, which is extensively used for imaging, is also a source of short-range Auger electrons (AE). While exhibiting negligible effect outside cells, these AE become highly toxic near DNA within the cell nucleus. Therefore, these radionuclides can be used as a therapeutic anticancer agent if delivered precisely into the nuclei of tumor target cells. Modular nanotransporters (MNTs) designed to provide receptor-targeted delivery of short-range therapeutic cargoes into the nuclei of target cells are perspective candidates for specific intracellular delivery of AE emitters. The objective of this study was to evaluate the in vitro and in vivo efficacy of 111In attached MNTs to kill human bladder cancer cells overexpressing epidermal growth factor receptor (EGFR). The cytotoxicity of 111In delivered by the EGFR-targeted MNT (111In-MNT) was greatly enhanced on EJ-, HT-1376-, and 5637-expressing EGFR bladder cancer cell lines compared with 111In non-targeted control. In vivo microSPECT/CT imaging and antitumor efficacy studies revealed prolonged intratumoral retention of 111In-MNT with t½ = 4.1 ± 0.5 days as well as significant dose-dependent tumor growth delay (up to 90% growth inhibition) after local infusion of 111In-MNT in EJ xenograft-bearing mice.

show abstract

Section: Introductionmentioning

confidence: 99%

Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Partial response was reported in 4% to 7.1%, stable disease in 17.9%-28% and progressive disease in 50%-56%[ 56 ]. Another study of 14 patients with metastatic NETs who received indium in-111 octreotide showed stable disease in 50 % of cases, partial response in 14%, and disease progression in 36%[ 64 ]. A quality-of-life study in 13 of these patients found a significant benefit in this[ 65 , 66 ].…”

Section: Treatment/managementmentioning

confidence: 99%

Vasoactive intestinal peptide secreting tumour: An overview

Cidon¹

2022

WJGO

View full text Add to dashboard Cite

Vasoactive intestinal peptide (VIP) secreting tumour (VIPoma) is a rare functional neuroendocrine tumour that typically arises from pancreatic islet cells. These present as sporadic, solitary pancreatic neoplasias with an estimated incidence of one in ten million individuals per year. Only around 5% of VIPomas are associated with multiple endocrine neoplasia type I syndrome. Excessive VIP secretion produces a clinical syndrome characterized by refractory watery diarrhoea, hypokalemia and metabolic acidosis. These coupled with elevated plasma levels of VIP are diagnostic. The majority of VIPomas are malignant and have already metastasized at the time of diagnosis (60%). Metastases occur most frequently in the liver, or regional lymph nodes, lungs, kidneys and bones. Some reports of skin metastases have been documented. Complete surgical resection continues to be the only potentially curative treatment. However, when the neoplasia cannot be excised completely, surgical debulking may provide palliative benefit. Other palliative options have included recently the peptide receptor radionuclide therapy which has shown to be effective and well-tolerated. This article will review all aspects of pancreatic VIPomas highlighting aspects such as clinical presentation, diagnosis and management.

show abstract

Neuroendocrine Tumors: Therapy with Radiolabeled Peptides

et al. 2022

View full text Add to dashboard Cite

Efficacy of adding high-dose In-111 octreotide therapy during Sandostatin treatment in patients with disseminated neuroendocrine tumors: clinical results of 14 patients

Abstract: High-dose In-111 octreotide can be safely administered in conjunction with somatostatin analogue in patients with disseminated NET and this treatment may help to stabilize the disease.

Cited by 8 publications

References 32 publications

Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression

Antitumor Activity of Auger Electron Emitter 111In Delivered by Modular Nanotransporter for Treatment of Bladder Cancer With EGFR Overexpression

Vasoactive intestinal peptide secreting tumour: An overview

Neuroendocrine Tumors: Therapy with Radiolabeled Peptides

Contact Info

Product

Resources

About